A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)
← catalyst calendarNCT07801300 · readout ≤ 361 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
204estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-03
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- C-Reactive Protein
Interventions
- Drug: LY5625575 — also filed as ZMG-3003936
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
measured Baseline up to Day 24
Related
LLY · their whole pipeline · Who in Congress owns LLY? · Executive-branch trades in LLY
LLY's other studiesmost recently updated first
- A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone Phase 3 · Completed
- A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) Phase 1 · Recruiting
- A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine Phase 3 · Terminated
- A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy Phase 1 · Recruiting
- A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes Phase 2 · Terminated
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed